Currently, serum (plasma) osteocalcin (N-MID) is widely recognized as a biomarker of bone formation and is commonly used to evaluate the efficacy of anti-resorptive therapies for conditions such as osteoporosis and hypercalcemia. The gene discussed is BGLAP; the disease is osteoporosis.